Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
Real-time Estimate Cboe Europe  -  05:45 2022-11-29 am EST
11151.00 GBX   +0.91%
04:55aTestimony by BOE's Bailey Could Move Sterling
DJ
04:31aAstraZeneca to acquire Neogene Therapeutics, accelerating ambition in Oncology cell therapy
AQ
04:06aTOP NEWS: AstraZeneca to buy Neogene for cancer treatment
AN
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Days
:
Hours
:
Minutes
:
Seconds

ASTRAZENECA : Deutsche Bank reiterates its Buy rating

09/21/2022 | 06:36am EST

In his latest research note, analyst Emmanuel Papadakis confirms his positive recommendation. The broker Deutsche Bank is keeping its Buy rating. The target price is unchanged and still at GBX 12000.


ę MarketScreener with dpa-AFX Analyser 2022
All news about ASTRAZENECA PLC
04:55aTestimony by BOE's Bailey Could Move Sterling
DJ
04:31aAstraZeneca to acquire Neogene Therapeutics, accelerating ambition in Oncology cell the..
AQ
04:06aTOP NEWS: AstraZeneca to buy Neogene for cancer treatment
AN
04:05aAstraZeneca Strengthens Cancer Pipeline Via $320 Million Neogene Therapeutics Buy
MT
04:00aLONDON MARKET OPEN: Stocks up as protests in China deterred by police
AN
03:56aUK Will Need Foreign Investors to Absorb Gilt Supply in 2023
DJ
03:11aLondon Stocks Seen Higher as Asia Gains on China Hopes
DJ
02:52aLONDON BRIEFING: easyJet boasts "record bounce back" as loss narrows
AN
02:38aAstraZeneca to Buy Neogene Therapeutics for $320 Million
DJ
02:34aAstraZeneca boosts cancer portfolio with $320 mln Neogene deal
RE
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2022 44 442 M - -
Net income 2022 4 087 M - -
Net Debt 2022 23 636 M - -
P/E ratio 2022 47,6x
Yield 2022 2,22%
Capitalization 206 B 206 B -
EV / Sales 2022 5,16x
EV / Sales 2023 4,84x
Nbr of Employees 83 100
Free-Float 96,5%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 26
Last Close Price 132,88 $
Average target price 144,81 $
Spread / Average Target 8,98%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC27.33%205 902
JOHNSON & JOHNSON3.66%463 626
ELI LILLY AND COMPANY32.23%347 547
ABBVIE INC.17.01%280 085
PFIZER, INC.-16.05%278 252
MERCK & CO., INC.41.51%274 964